BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines External R&D — BGB-A445 (Anti-OX40 Agonist) by Year
External R&D — BGB-A445 (Anti-OX40 Agonist) ($M, FY20–FY23) ($M)
BeOne Medicines External R&D — BGB-A445 (Anti-OX40 Agonist): $15.8M in FY2023, up 40.5% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“|| OX40 (BGB-A445) | 15,757 | 11,215”
Reported in Form 8-K EX-99.1 SSE STAR Market Annual Reports (688235.SS).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | External R&D — BGB-A445 (Anti-OX40 Agonist) ($M, FY20–FY23) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 15.8 | +40.5% | 8-K STAR Report (2024-04-26, 0001651308-24-000043) ↗ |
| FY2022 | Dec 31, 2022 | 11.2 | +404.0% | 8-K STAR Report (2024-04-26, 0001651308-24-000043) ↗ |
| FY2021 | Dec 31, 2021 | 2.23 | -26.1% | 8-K STAR Report (2023-04-25, 0001651308-23-000061) ↗ |
| FY2020 | Dec 31, 2020 | 3.01 | – | 8-K STAR Report (2022-04-28, 0001651308-22-000058) ↗ |
Cite this data
StockData. (2026). BeOne Medicines External R&D — BGB-A445 (Anti-OX40 Agonist) ($M), annual FY2020–FY2023 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-mol-ox40
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.